Ma Huang and ephedra Rx-only status urged by state officials .
This article was originally published in The Tan Sheet
Executive Summary
STATE OFFICIALS URGE FDA TO LIMIT MA HUANG TO Rx USE ONLY in an Aug. 4 letter to the agency. The comments from the National Association of State Controlled Substances Authorities were in response to FDA's July 27 Federal Register notice proposing the removal of ephedrine from the bronchodilator drug products monograph because of the ingredient's use as a precursor in the manufacture of controlled substances such as methamphetamine and methcathinone ("The Tan Sheet" July 31, p. 1). FDA has extended the comment period on the proposed rulemaking to Sept. 27 .
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning